Eisai Company, Ltd. Enters Two Joint Research Agreements To Develop New Antimalarial Medicines

Tokyo, Sept 16, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has entered into two joint research agreements for the development of new antimalarial medicines.

The first of these agreements is a joint development program with St. Jude Children's Research Hospital (Memphis, Tennessee, United States, "St. Jude") and the non-profit public-private partnership Medicines for Malaria Venture (Geneva, Switzerland, "MMV"). Under this agreement, the three parties will conduct preclinical and clinical development of the oral antimalarial candidate compound SJ733. In addition to being rapidly effective and having the potential to cure in a single dose, SJ733 is non-artemisinin based, which means it could also be effective in patients for whom existing artemisinin-based malaria treatments have little effect due to recently increasing resistance.

Help employers find you! Check out all the jobs and post your resume.